Compare ECF & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ECF | HURA |
|---|---|---|
| Founded | 1986 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.7M | 160.5M |
| IPO Year | N/A | 2010 |
| Metric | ECF | HURA |
|---|---|---|
| Price | $11.75 | $1.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.04 |
| AVG Volume (30 Days) | 44.5K | ★ 211.8K |
| Earning Date | 01-01-0001 | 11-13-2026 |
| Dividend Yield | ★ 6.42% | N/A |
| EPS Growth | N/A | ★ 47.93 |
| EPS | ★ 0.46 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $26.09 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.71 | $0.41 |
| 52 Week High | $13.85 | $3.43 |
| Indicator | ECF | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 37.77 | 34.17 |
| Support Level | $11.16 | $1.27 |
| Resistance Level | $12.68 | $1.83 |
| Average True Range (ATR) | 0.18 | 0.10 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 11.20 | 14.93 |
Ellsworth Growth and Income Fund Ltd operate as a closed-end, diversified management investment company. Its investment objective is to provide income and the potential for capital appreciation, which objectives the Fund considers to be relatively equal over the long term due to the nature of the securities in which it invests. The company invests in convertible and equity securities. It invests in various sectors, such as healthcare, financial services, computer software and services, energy and utilities, real estate investment trusts, semiconductors, telecommunications, business services, food and beverage, consumer products, transportation, consumer services among others.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.